Drug-eluting Balloon Catheters Market Size - By Product [Coronary Artery & Peripheral Vascular Disease Catheters (Paclitaxel, Sirolimus)], Material (Polyurethane, Nylon), End-use & Global Forecast, 2023-2032

Drug-eluting Balloon Catheters Market Size - By Product [Coronary Artery & Peripheral Vascular Disease Catheters (Paclitaxel, Sirolimus)], Material (Polyurethane, Nylon), End-use & Global Forecast, 2023-2032

Drug-eluting Balloon Catheters Market Size

Drug-eluting Balloon Catheters Market size was valued at around USD 582 million in 2022 and is estimated to witness 11.5% CAGR between 2023 and 2032. The high industry expansion can be primarily attributed to factors including advancements in drug delivery technologies, growing trend towards minimally invasive procedures, rising awareness and increasing incidence of cardiovascular diseases among others.
 

According to the World Health Organization (WHO), cardiovascular diseases are a leading cause of mortality globally, accounting for a significant percentage of deaths. For instance, as per the 2023 report by Centers for Disease Control and Prevention (CDC), there were around 0.7 million deaths from heart related diseases in the U.S.
 

Moreover, ongoing advancements in drug delivery technologies contribute to the development of more effective and targeted drug-eluting balloon catheters. Drug-eluting balloon catheters, with their anti-proliferative drug coatings, aim to reduce the incidence of restenosis compared to traditional angioplasty. Furthermore, increasing awareness among healthcare professionals and patients about the benefits of drug-eluting balloon catheters contributes to higher adoption rates.
 

Drug eluting balloon catheters or drug coated balloons aide in treating hyperplasia. The catheter carries an antiproliferative drug, usually paclitaxel or sirolimus that is delivered to the arterial walls as the balloon expands. Additionally, it offers controlled drug delivery to treat cardiovascular or peripheral diseases.

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the market. Various elective procedures, including some cardiovascular interventions, were delayed or postponed during the height of the pandemic due to concerns about the spread of the virus and the strain on healthcare resources. The global disruptions in supply chains caused by the pandemic have affected the production and distribution of medical devices.
 

Drug-eluting Balloon Catheters Market Trends

Improved drug delivery systems, biodegradable technologies, and customized drug formulations among other key technological advancements are anticipated to shape the industry.
 

• Improved mechanical properties, such as increased flexibility and better navigation, contribute to more precise interventions and increased efficacy of drug delivery. Enhanced drug delivery systems result in more targeted and controlled release of therapeutic agents, improving the effectiveness of drug-eluting balloon catheters in preventing restenosis.
   
• Development of advanced coatings, including nano-coatings and biodegradable polymers contribute to better adhesion, controlled drug release kinetics, and improved biocompatibility.
   

Drug-eluting Balloon Catheters Market Analysis

The market by product is categorized into coronary artery disease DEB catheters, and peripheral vascular disease DEB catheters. The peripheral vascular disease DEB catheters segment held leading revenue share and was valued at over USD 323 million in 2022.
 

• DEB catheters, with their drug-coated technology, have the ability to minimize the risk of restenosis, is a significant factor driving the adoption of DEB catheters for peripheral vascular disease interventions.
   
• Research and clinical experience supporting the use of DEB catheters in a broader range of peripheral vessels including treatment of various types of peripheral arterial lesions.
   
• Peripheral vascular disease DEB catheters, often used in minimally invasive procedures, align well with the trend toward outpatient interventions, leading to increased demand for wide range of procedures.
   

Based on material, the drug-eluting balloon catheters market is segmented into polyurethane, nylon, and other materials. The polyurethane segment accounted for significant share in 2022 and was valued at over USD 204 million.
 

• Polyurethane offers good flexibility, allowing the catheter to navigate through tortuous vessels. Improved flexibility enhances the maneuverability of drug-eluting balloon catheters, making them suitable for a variety of vascular anatomies.
   
• Some polyurethane formulations can be made radiopaque as radiopacity is crucial for visualization during procedures, allowing healthcare professionals to monitor the catheter's position using fluoroscopy or other medical imaging techniques
   
• Positive clinical outcomes with polyurethane-based drug-eluting balloon catheters in clinical studies and real-world scenarios.

The drug-eluting balloon catheters market by end-use is categorized into hospitals and clinics, ambulatory surgical centers, and catheterization laboratories. The hospitals and clinics segment is projected to reach over USD 964 million revenue size in 2032.
 

• Drug-eluting balloon catheters offer a minimally invasive alternative to traditional interventions, such as open-heart surgery or bypass procedures. Patients often prefer less invasive options, and healthcare providers are increasingly adopting these catheters for procedures in hospitals and clinics.
   
• Drug-eluting balloon catheters, by delivering therapeutic agents to the treated site, aim to reduce the risk of restenosis (re-narrowing of the blood vessel). The potential for improved long-term outcomes makes these catheters appealing for use in these healthcare settings.
   
• Favorable reimbursement policies for procedures involving drug-eluting balloon catheters encourages healthcare providers to offer these interventions in hospitals and clinics.

North America drug-eluting balloon catheters market accounted for USD 254.9 million revenue in 2022.
 

• The aging population is more prone to cardiovascular diseases and as the population ages, there is a corresponding increase in the demand for interventions, including drug-eluting balloon catheters, to address cardiovascular conditions. For instance, there are more than 350,000 Coronary artery bypass graft surgery (CABG) surgeries performed each year in the U.S.
   
• Drug-eluting balloon catheters are used for the treatment of complex lesions, including in-stent restenosis. The effectiveness in addressing challenging cases contributes to the adoption of these catheters in regional healthcare settings.
   
• Growing awareness among healthcare professionals and patients about advanced interventional options coupled with increased understanding of the benefits of drug-eluting balloon catheters.
   

Drug-eluting Balloon Catheters Market Share

The drug-eluting balloon catheters industry is fairly consolidated in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Boston Scientific Corporation, Medtronic, Biotronik AG and B. Braun Melsungen AG have a notable presence in the industry.

Some of the eminent market participants operating in the drug-eluting balloon catheters industry include

• Aachen Resonance GmbH
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Eurocor GmbH
• iVascular S.L.U.
• Zhejiang Barty Medical Technology Co.Ltd
• Lepu Medical Technology(Beijing) Co. Ltd.
• MedAlliance
• Medtronic plc
   

Drug-eluting Balloon Catheters Industry News

• In October 2023, MedAlliance, a Swiss-based medical technology company has been acquired by Cordis for a total consideration of over USD 1.1 billion.
   
• In June 2023, Translumina, a company operating in interventional cardiovascular medical devices, announced to acquire Blue Medical Devices, a Wellinq group company. Blue Medical Devices manufactures range of balloon catheters including drug coated balloons (DCB) and various other specialty balloons used in complex coronary interventions.
   

Drug-eluting balloon catheters market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product, 2018-2032 (USD Million)

• Coronary Artery Disease Drug Eluting Balloon Catheters
  • Paclitaxel
  • Sirolimus 
• Peripheral Vascular Disease Drug Eluting Balloon Catheters
  • Paclitaxel
  • Sirolimus

By Material, 2018-2032 (USD Million)

• Polyurethane
• Nylon
• Other materials

By End-use, 2018-2032 (USD Million)

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Catheterization Laboratories

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA